Cargando…

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients

Until now, the anatomic extent of tumor (TNM classification) has been, by far, the most important factor to predict the prognosis of colorectal cancer patients. However, in recent years, data collected from large cohorts of human cancers demonstrated that the immune contexture of the primary tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Bindea, Gabriela, Mlecnik, Bernhard, Fridman, Wolf-Herman, Galon, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139059/
https://www.ncbi.nlm.nih.gov/pubmed/21461991
http://dx.doi.org/10.1007/s00281-011-0264-x
_version_ 1782208418595995648
author Bindea, Gabriela
Mlecnik, Bernhard
Fridman, Wolf-Herman
Galon, Jérôme
author_facet Bindea, Gabriela
Mlecnik, Bernhard
Fridman, Wolf-Herman
Galon, Jérôme
author_sort Bindea, Gabriela
collection PubMed
description Until now, the anatomic extent of tumor (TNM classification) has been, by far, the most important factor to predict the prognosis of colorectal cancer patients. However, in recent years, data collected from large cohorts of human cancers demonstrated that the immune contexture of the primary tumors is an essential prognostic factor for patients' disease-free and overall survival. Global analysis of tumor microenvironment showed that the nature, the functional orientation, the density, and the location of adaptive immune cells within distinct tumor regions influence the risk of relapse events. An immune classification of the patients was proposed based on the density and the immune cell location within the tumor. The immune classification has a prognostic value that is superior to the TNM classification, and tumor invasion is statistically dependent on the host immune reaction. Tumor and immunological markers predicted by systems biology methods are involved in the shaping of an efficient immune reaction and can serve as targets for novel therapeutic approaches. Thus, the strength of the immune reaction could advance our understanding of cancer evolution and have important consequences in clinical practice.
format Online
Article
Text
id pubmed-3139059
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-31390592011-08-26 The prognostic impact of anti-cancer immune response: a novel classification of cancer patients Bindea, Gabriela Mlecnik, Bernhard Fridman, Wolf-Herman Galon, Jérôme Semin Immunopathol Review Until now, the anatomic extent of tumor (TNM classification) has been, by far, the most important factor to predict the prognosis of colorectal cancer patients. However, in recent years, data collected from large cohorts of human cancers demonstrated that the immune contexture of the primary tumors is an essential prognostic factor for patients' disease-free and overall survival. Global analysis of tumor microenvironment showed that the nature, the functional orientation, the density, and the location of adaptive immune cells within distinct tumor regions influence the risk of relapse events. An immune classification of the patients was proposed based on the density and the immune cell location within the tumor. The immune classification has a prognostic value that is superior to the TNM classification, and tumor invasion is statistically dependent on the host immune reaction. Tumor and immunological markers predicted by systems biology methods are involved in the shaping of an efficient immune reaction and can serve as targets for novel therapeutic approaches. Thus, the strength of the immune reaction could advance our understanding of cancer evolution and have important consequences in clinical practice. Springer-Verlag 2011-04-05 2011 /pmc/articles/PMC3139059/ /pubmed/21461991 http://dx.doi.org/10.1007/s00281-011-0264-x Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review
Bindea, Gabriela
Mlecnik, Bernhard
Fridman, Wolf-Herman
Galon, Jérôme
The prognostic impact of anti-cancer immune response: a novel classification of cancer patients
title The prognostic impact of anti-cancer immune response: a novel classification of cancer patients
title_full The prognostic impact of anti-cancer immune response: a novel classification of cancer patients
title_fullStr The prognostic impact of anti-cancer immune response: a novel classification of cancer patients
title_full_unstemmed The prognostic impact of anti-cancer immune response: a novel classification of cancer patients
title_short The prognostic impact of anti-cancer immune response: a novel classification of cancer patients
title_sort prognostic impact of anti-cancer immune response: a novel classification of cancer patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139059/
https://www.ncbi.nlm.nih.gov/pubmed/21461991
http://dx.doi.org/10.1007/s00281-011-0264-x
work_keys_str_mv AT bindeagabriela theprognosticimpactofanticancerimmuneresponseanovelclassificationofcancerpatients
AT mlecnikbernhard theprognosticimpactofanticancerimmuneresponseanovelclassificationofcancerpatients
AT fridmanwolfherman theprognosticimpactofanticancerimmuneresponseanovelclassificationofcancerpatients
AT galonjerome theprognosticimpactofanticancerimmuneresponseanovelclassificationofcancerpatients
AT bindeagabriela prognosticimpactofanticancerimmuneresponseanovelclassificationofcancerpatients
AT mlecnikbernhard prognosticimpactofanticancerimmuneresponseanovelclassificationofcancerpatients
AT fridmanwolfherman prognosticimpactofanticancerimmuneresponseanovelclassificationofcancerpatients
AT galonjerome prognosticimpactofanticancerimmuneresponseanovelclassificationofcancerpatients